Form 4: Nektar Therapeutics Executive Sells Shares for Tax

Chief R&D Officer Jonathan Zalevsky sold 199 shares of Nektar Therapeutics to cover tax withholding obligations related to RSU vesting.

Summary

• Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics, sold 199 shares of common stock.
• The sale occurred on May 19, 2026, at a weighted average price of $65.51 per share.
• The transaction was executed to satisfy mandatory tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person retains beneficial ownership of 20,975 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and mandatory for tax purposes.

Positives

• The transaction was non-discretionary, specifically executed to cover tax liabilities rather than reflecting a change in investment sentiment.

Negatives

• Reduction in the total number of shares held by a key member of the executive leadership team.

Risks

• None identified; this is a routine administrative transaction related to equity compensation.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Management Comments

• The transaction was executed in multiple trades at prices ranging from $64.88 to $68.43.

Industry Context

StockSavvy.ai notes that this is a standard 'sell-to-cover' transaction common in the biotechnology sector, where executives frequently receive equity-based compensation that triggers immediate tax liabilities upon vesting.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for handling RSU tax obligations.
• The volume of shares sold is immaterial relative to the total outstanding shares of Nektar Therapeutics.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary and small in volume.

Next Steps

• None mentioned.

Key Dates

Keywords

Nektar Therapeutics, NKTR, Insider Trading, Form 4, Equity Compensation, Tax Withholding